Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 7/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16249227 | 1.00 | KCNH2 (0.46) | KCNH2CACNA1GCACNA1HALOX15HTT | |
| SCHEMBL17259221 | 0.87 | KCNH2 (0.40) | KCNH2CACNA1GCACNA1HALOX15HTT | |
| SCHEMBL17259220 | 0.87 | KCNH2 (0.40) | KCNH2CACNA1GCACNA1HALOX15HTT | |
| SCHEMBL3300596 | 0.82 | KCNH2 (0.52) | KCNH2CACNA1GCACNA1HHTR6GAA | |
| SCHEMBL23402955 | 0.77 | KCNH2 (0.52) | KCNH2CACNA1GCACNA1HHTR6GAA | |
| SCHEMBL17259259 | 0.74 | KCNH2 (0.60) | KCNH2CACNA1GCACNA1HP2RX7HTR6 | |
| SCHEMBL16241332 | 0.73 | ALDH1A1 (0.55) | KCNH2CACNA1GCACNA1HHTR6GAA | |
| SCHEMBL3300740 | 0.71 | KCNH2 (0.60) | KCNH2CACNA1GCACNA1HHTR6GAA | |
| SCHEMBL17259261 | 0.71 | KCNH2 (0.60) | KCNH2CACNA1GCACNA1HHTR6GAA | |
| SCHEMBL17259227 | 0.69 | KCNH2 (0.67) | KCNH2CACNA1GCACNA1HHTR6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493423-B2 | Compounds capable of inhibiting voltage gated calcium ion channel, and pharmaceutical compositions comprising the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2016-11-15 | — | — | US | disclosed |
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329533-A1 | COMPOUNDS CAPABLE OF INHIBITING VOLTAGE GATED CALCIUM ION CHANNEL, AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CACNA1B, CACNA1F, CACNA1G | KCNH2 33/4885CACNA1G 3/4885CACNA1H 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.